[go: up one dir, main page]

WO2007067512A3 - Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer - Google Patents

Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer Download PDF

Info

Publication number
WO2007067512A3
WO2007067512A3 PCT/US2006/046331 US2006046331W WO2007067512A3 WO 2007067512 A3 WO2007067512 A3 WO 2007067512A3 US 2006046331 W US2006046331 W US 2006046331W WO 2007067512 A3 WO2007067512 A3 WO 2007067512A3
Authority
WO
WIPO (PCT)
Prior art keywords
adprh
useful
disease
treating alzheimer
identifying modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046331
Other languages
English (en)
Other versions
WO2007067512A2 (fr
Inventor
John M Majercak
William J Ray
David J Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2007067512A2 publication Critical patent/WO2007067512A2/fr
Publication of WO2007067512A3 publication Critical patent/WO2007067512A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour identifier des modulateurs d'ADPRH. Ces procédés conviennent particulièrement pour identifier des analysats antagonistes de l'effet d'ADPRH sur la maturation de la protéine précurseur d'amyloïde en peptide AjS et donc pour identifier des analysats convenant pour traiter la maladie d'Alzheimer.
PCT/US2006/046331 2005-12-08 2006-12-04 Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer Ceased WO2007067512A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74846505P 2005-12-08 2005-12-08
US60/748,465 2005-12-08

Publications (2)

Publication Number Publication Date
WO2007067512A2 WO2007067512A2 (fr) 2007-06-14
WO2007067512A3 true WO2007067512A3 (fr) 2007-12-13

Family

ID=38123413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046331 Ceased WO2007067512A2 (fr) 2005-12-08 2006-12-04 Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer

Country Status (1)

Country Link
WO (1) WO2007067512A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US20030200555A1 (en) * 2001-05-22 2003-10-23 Hazuda Daria Jean Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
US20050019330A1 (en) * 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2005098433A2 (fr) * 2004-04-01 2005-10-20 Novartis Ag Methodes diagnostiques de la maladie d'alzheimer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019330A1 (en) * 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030200555A1 (en) * 2001-05-22 2003-10-23 Hazuda Daria Jean Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
WO2005098433A2 (fr) * 2004-04-01 2005-10-20 Novartis Ag Methodes diagnostiques de la maladie d'alzheimer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOVE ET AL.: "Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease", BRAIN, vol. 122, 1 February 1999 (1999-02-01), pages 247 - 253, XP002233086 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO2007067512A2 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2008076262A3 (fr) Récepteur pour bêta amyloïde et utilisations de celui-ci
WO2006138659A3 (fr) Sonde a lumiere rouge intranasale pour le traitement de la maladie d'alzheimer
WO2007064972A3 (fr) Anticorps monoclonaux et utilisation de ceux-ci
EP1877175A4 (fr) Appareil et procede de fabrication de produits radiopharmaceutiques
DE60332024D1 (de) Verfahren zur herstellung von soja protein
WO2009098682A3 (fr) Procédés et compositions de traitement des maladies mitochondriales
WO2007001264A3 (fr) Procede pour produire des anticorps humain de recombinaison utilises dans le cadre d'une technologie de biocapteur
DE60237242D1 (de) Hilfsverfahren, hilfsprogramm und hilfsvorrichtung zur bildanalyse
EP1668125A4 (fr) Enzymes modifiées, procédés de production d'enzymes modifiées et utilisations de ces dernières
WO2007070604A3 (fr) Systeme et procede pour fournir un contenu et des services a grande vitesse
DE602004004334D1 (de) Bearbeitungsverfahren zur Bearbeitung von gewölbten Oberflächen
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
WO2004093790A3 (fr) Proteines traitees anormalement exprimant de maniere ectopique la levure et leurs utilisations
EP1651237A4 (fr) Methodes de traitement de troubles dermatologiques
WO2007067512A3 (fr) Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer
WO2007008073A3 (fr) Methodes de determination de l'effet d'un traitement sur la teneur d'une proteine a structure croisee $g(b); selection des traitements et leurs utilisations
AU2003903242A0 (en) Process for the treatment of wood
WO2007019312A3 (fr) Methodes permettant de caracteriser et de traiter un trouble cognitif du au vieillissement ou une maladie
DE60220554D1 (de) Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
DE602005013895D1 (de) Vorrichtung zur Herstellung von Reifenbestandteilen.
WO2007010110A3 (fr) Procede de detection des fpca utilisant un agent d'agregation des fpca et un agent de capture des agregats formes
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
WO2006138363A3 (fr) Methode destinee a identifier des modulateurs de keah6 utiles pour traiter la maladie d'alzheimer
WO2006094134A3 (fr) Anticorps kim-1 utilises dans le traitement des etats induits par th2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847499

Country of ref document: EP

Kind code of ref document: A2